Embecta gets FDA clearance for type 2 diabetes patch pump

seekingalpha09-03

Embecta (NASDAQ:EMBC) has received FDA clearance for its disposable insulin delivery system for the treatment of both type 1 and type 2 diabetes. The system includes a tubeless patch pump with a 300-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2464869643?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215516118/image_1215516118.jpg","is_english":true,"pubTime":"2024-09-03 22:24","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2464869643","market":"nz","top_or_hot":-1,"title":"Embecta gets FDA clearance for type 2 diabetes patch pump","media":"seekingalpha","content":"<div>\n<p>Embecta (NASDAQ:EMBC) has received FDA clearance for its disposable insulin delivery system for the treatment of both type 1 and type 2 diabetes. The system includes a tubeless patch pump with a 300-...</p>\n\n<a href=\"https://seekingalpha.com/news/4146224-embecta-gets-fda-clearance-for-type-2-diabetes-patch-pump\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Embecta gets FDA clearance for type 2 diabetes patch pump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmbecta gets FDA clearance for type 2 diabetes patch pump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-03 22:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4146224-embecta-gets-fda-clearance-for-type-2-diabetes-patch-pump><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Embecta (NASDAQ:EMBC) has received FDA clearance for its disposable insulin delivery system for the treatment of both type 1 and type 2 diabetes. The system includes a tubeless patch pump with a 300-...</p>\n\n<a href=\"https://seekingalpha.com/news/4146224-embecta-gets-fda-clearance-for-type-2-diabetes-patch-pump\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PODD","symbol_name":"银休特","start_time":0,"source_url":"https://seekingalpha.com/news/4146224-embecta-gets-fda-clearance-for-type-2-diabetes-patch-pump","article_id":"2464869643","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215516118/image_1215516118.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2464869643","pubTimestamp":1725373472,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Embecta  has received FDA clearance for its disposable insulin delivery system for the treatment of both type 1 and type 2 diabetes. The system includes a tubeless patch pump with a 300-unit insulin reservoir and a locked-down controller with Bluetooth technology.   Embecta said the 300-unit reservoir design is aimed at accommodating the needs of type 2 diabetics who have higher daily insulin needs, according to a statement. Embecta added it is also working on a closed-loop patch pump device that includes an insulin-dosing algorithm.  Wells Fargo pointed out that Insulet  recently received FDA clearance for its Omnipod 5 insulin delivery system for type 2 diabetes, while Tandem Diabetes Care  expects to submit an application to get its device approved for type 2 diabetes “shortly.” The investment bank noted that Insulet’s Omnipod 5 only has a 200-unit reservoir versus Embecta’s 300-unit.  “This is important because people with type 2 tend to use more insulin,” the bank added.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PODD":"银休特","BK4082":"医疗保健设备","BK4585":"ETF&股票定投概念","TNDM":"糖尿病保健","BK4588":"碎股","BK4198":"医疗保健用品","BK4566":"资本集团","EMBC":"Embecta Corp.","BK4551":"寇图资本持仓"},"translate_title":"Embecta 2型糖尿病贴片泵获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMBC":1,"PODD":1,"TNDM":1},"content_text":"Embecta (NASDAQ:EMBC) has received FDA clearance for its disposable insulin delivery system for the treatment of both type 1 and type 2 diabetes. The system includes a tubeless patch pump with a 300-unit insulin reservoir and a locked-down controller with Bluetooth technology.   Embecta said the 300-unit reservoir design is aimed at accommodating the needs of type 2 diabetics who have higher daily insulin needs, according to a statement. Embecta added it is also working on a closed-loop patch pump device that includes an insulin-dosing algorithm.  Wells Fargo pointed out that Insulet (PODD) recently received FDA clearance for its Omnipod 5 insulin delivery system for type 2 diabetes, while Tandem Diabetes Care (TNDM) expects to submit an application to get its device approved for type 2 diabetes “shortly.” The investment bank noted that Insulet’s Omnipod 5 only has a 200-unit reservoir versus Embecta’s 300-unit.  “This is important because people with type 2 tend to use more insulin,” the bank added.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2464869643"}